SI3429559T1 - Okusni sestavki, ki vključujejo natrijev fenilbutirat, in njihove uporabe - Google Patents

Okusni sestavki, ki vključujejo natrijev fenilbutirat, in njihove uporabe

Info

Publication number
SI3429559T1
SI3429559T1 SI201631567T SI201631567T SI3429559T1 SI 3429559 T1 SI3429559 T1 SI 3429559T1 SI 201631567 T SI201631567 T SI 201631567T SI 201631567 T SI201631567 T SI 201631567T SI 3429559 T1 SI3429559 T1 SI 3429559T1
Authority
SI
Slovenia
Prior art keywords
flavor compositions
sodium phenylbutyrate
phenylbutyrate
sodium
flavor
Prior art date
Application number
SI201631567T
Other languages
English (en)
Slovenian (sl)
Inventor
Leah E. Appel
Joshua R. Shockey
D. Christopher SCHELLING
Original Assignee
Acer Therapeutics Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acer Therapeutics Inc. filed Critical Acer Therapeutics Inc.
Publication of SI3429559T1 publication Critical patent/SI3429559T1/sl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1641Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/501Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5026Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089Processes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
SI201631567T 2016-03-15 2016-10-17 Okusni sestavki, ki vključujejo natrijev fenilbutirat, in njihove uporabe SI3429559T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662308614P 2016-03-15 2016-03-15
EP16894786.9A EP3429559B1 (en) 2016-03-15 2016-10-17 Palatable compositions including sodium phenylbutyrate and uses thereof
PCT/US2016/057415 WO2017160345A1 (en) 2016-03-15 2016-10-17 Palatable compositions including sodium phenylbutyrate and uses thereof

Publications (1)

Publication Number Publication Date
SI3429559T1 true SI3429559T1 (sl) 2022-11-30

Family

ID=59847918

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201631567T SI3429559T1 (sl) 2016-03-15 2016-10-17 Okusni sestavki, ki vključujejo natrijev fenilbutirat, in njihove uporabe

Country Status (22)

Country Link
US (6) US20170266115A1 (https=)
EP (2) EP4104822A1 (https=)
JP (4) JP7136763B2 (https=)
KR (3) KR20250150154A (https=)
AU (1) AU2016398029B2 (https=)
BR (1) BR112018068665B1 (https=)
CY (1) CY1125450T1 (https=)
DK (1) DK3429559T3 (https=)
ES (1) ES2922749T3 (https=)
HR (1) HRP20220856T1 (https=)
HU (1) HUE059630T2 (https=)
IL (3) IL296490B2 (https=)
LT (1) LT3429559T (https=)
MX (2) MX391305B (https=)
PL (1) PL3429559T3 (https=)
PT (1) PT3429559T (https=)
RS (1) RS63383B1 (https=)
SA (1) SA518400020B1 (https=)
SG (1) SG11201807979SA (https=)
SI (1) SI3429559T1 (https=)
SM (1) SMT202200386T1 (https=)
WO (1) WO2017160345A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250150154A (ko) 2016-03-15 2025-10-17 에이서 테라퓨틱스 인크. 소듐 페닐부티레이트를 포함하는 맛우수한 조성물 및 그의 용도
US11583542B2 (en) * 2019-12-16 2023-02-21 Amylyx Pharmaceuticals, Inc. Compositions of bile acids and phenylbutyrate compounds
CA3184989A1 (en) * 2020-07-07 2022-01-13 Christopher D. Schelling Methods of administering taste masked phenylbutyrate and compositions therefor
JP2023553274A (ja) * 2020-11-18 2023-12-21 エフビー-エイチアールエス リミテッド ライアビリティ カンパニー ドフェチリド及びメキシレチンを含有する組成物並びにその使用
CN113332267A (zh) * 2021-03-31 2021-09-03 中山大学孙逸仙纪念医院 苯丁酸钠在制备预防或治疗帕金森病的药物中的应用
IT202100019613A1 (it) 2021-07-23 2023-01-23 Kolfarma S R L Formulazione farmaceutica o di integratore alimentare contenente alfa-lattoalbumina e acido butirrico o un suo sale
CN216570857U (zh) * 2021-08-11 2022-05-24 Acer治疗公司 改善药物物质适口性的剂型和多个剂型
IL315049A (en) * 2024-08-15 2026-03-01 Prilenia Neurotherapeutics Ltd Taste-masking compounds containing pridopidine, their use and method for their preparation

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5910304A (en) 1982-12-13 1999-06-08 Texas A&M University System Low-dose oral administration of interferons
CA1320905C (en) 1986-11-06 1993-08-03 Joseph M. Cummins Treatment of immuno-resistant disease
US6036949A (en) 1998-03-05 2000-03-14 Amarillo Biosciences, Inc. Treatment of fibromyalgia with low doses of interferon
AR034813A1 (es) 2001-07-20 2004-03-17 Novartis Ag Composiciones farmaceuticas y uso de las mismas
EP1291015A1 (en) 2001-09-10 2003-03-12 Lunamed AG Dosage forms having prolonged active ingredient release
US20040152784A1 (en) * 2002-07-23 2004-08-05 Special Products Limited Pharmaceutical composition and method for treatment of a urea cycle deficiency or sickle-cell anaemia
FR2850275B1 (fr) * 2003-01-24 2005-04-08 Scherer Technologies Inc R P Capsules molles a macher contenant une substance active a gout masque
JP2005060310A (ja) * 2003-08-13 2005-03-10 Towa Yakuhin Kk 不快な味をマスキングする経口投与用製剤
US6984403B2 (en) 2003-12-04 2006-01-10 Pfizer Inc. Azithromycin dosage forms with reduced side effects
US8236349B2 (en) * 2004-04-12 2012-08-07 Bend Research Inc. Taste-masked drugs in rupturing multiparticulates
US8821928B2 (en) * 2007-06-04 2014-09-02 Egalet Ltd. Controlled release pharmaceutical compositions for prolonged effect
ES2332687B1 (es) 2008-03-13 2011-01-10 Proyecto De Biomedicina Cima, S.L. Nuevos usos de 4pba y sus sales farmaceuticamente aceptables.
US20100136110A1 (en) * 2008-09-30 2010-06-03 Astellas Pharma Inc. Granular pharmaceutical composition for oral administration
EP2954780A1 (en) * 2009-07-24 2015-12-16 Baylor College Of Medicine Methods of modulation of branched chain acids and uses thereof
FR2959129B1 (fr) * 2010-04-21 2013-02-01 Lucane Pharma Particules comprenant du 4-phenylbutyrate de sodium, procede de preparation et utilisations
EP2389932A1 (en) * 2010-05-28 2011-11-30 Lunamed AG Compositions for use in genetic disorders comprising 4-phenyl-butyric acid and its salts
CA2820178A1 (en) 2010-12-06 2012-06-14 Degama Berrier Ltd. Composition and method for improving stability and extending shelf life of probiotic bacteria and food products thereof
US8897280B2 (en) * 2011-03-29 2014-11-25 Qualcomm Incorporated System and method for clear channel assessment that supports simultaneous transmission by multiple wireless protocols
EP2709593A4 (en) * 2011-05-16 2014-10-29 Sun Pharma Advanced Res Co Ltd PHARMACEUTICAL COMPOSITION OF MULTIPLE PARTICLES
JP2012240917A (ja) * 2011-05-16 2012-12-10 Zensei Yakuhin Kogyo Kk 製剤化用微粒子とそれを含む製剤
AU2012265842A1 (en) 2011-06-07 2014-01-23 SPAI Group Ltd. Compositions and methods for improving stability and extending shelf life of sensitive food additives and food products thereof
WO2012175714A1 (en) * 2011-06-22 2012-12-27 Gmp-Orphan Phenylbutyrate in rectal form for the treatment of a motor neuron disease or a metabolic disease
AR089645A1 (es) * 2011-08-12 2014-09-10 Boehringer Ingelheim Vetmed Particula multicapas de sabor enmascarado, metodo, uso, composicion farmaceutica
EP2599477A1 (en) * 2011-11-30 2013-06-05 Lunamed AG 4-Phenylbutyric acid sustained release formulation
US8993041B2 (en) * 2012-10-15 2015-03-31 New Jersey Institute Of Technology Taste masked active pharmaceutical powder compositions and processes for making them
CN110302168A (zh) 2013-01-28 2019-10-08 万平 定位速释生物粘附剂及其制备方法和应用
JP6147711B2 (ja) * 2014-05-26 2017-06-14 富士フイルム株式会社 医薬用組成物及びその製造方法、並びに口腔内崩壊錠及びその製造方法
KR20250150154A (ko) 2016-03-15 2025-10-17 에이서 테라퓨틱스 인크. 소듐 페닐부티레이트를 포함하는 맛우수한 조성물 및 그의 용도

Also Published As

Publication number Publication date
EP3429559A4 (en) 2019-11-06
KR102690703B1 (ko) 2024-08-02
MX2022003969A (es) 2022-04-25
AU2016398029B2 (en) 2023-03-02
SG11201807979SA (en) 2018-10-30
MX2018011229A (es) 2019-05-30
IL296490B1 (en) 2025-09-01
AU2016398029A1 (en) 2018-10-11
HRP20220856T1 (hr) 2022-10-14
KR102865751B1 (ko) 2025-09-29
US20210220304A1 (en) 2021-07-22
JP7136763B2 (ja) 2022-09-13
LT3429559T (lt) 2022-08-10
CY1125450T1 (el) 2025-05-09
EP3429559B1 (en) 2022-04-13
RS63383B1 (sr) 2022-08-31
BR112018068665A2 (pt) 2019-02-05
US20230133629A1 (en) 2023-05-04
PT3429559T (pt) 2022-07-20
ES2922749T3 (es) 2022-09-20
IL296490B2 (en) 2026-01-01
SMT202200386T1 (it) 2022-11-18
JP2026027401A (ja) 2026-02-18
BR112018068665B1 (pt) 2023-12-26
EP4104822A1 (en) 2022-12-21
MX391305B (es) 2025-03-21
US20170266115A1 (en) 2017-09-21
JP2024081748A (ja) 2024-06-18
JP2019509345A (ja) 2019-04-04
US11433041B2 (en) 2022-09-06
IL322955A (en) 2025-10-01
KR20190008840A (ko) 2019-01-25
CA3017573A1 (en) 2017-09-21
US11202767B2 (en) 2021-12-21
EP3429559A1 (en) 2019-01-23
WO2017160345A8 (en) 2018-02-22
IL261777A (en) 2018-10-31
US11154521B2 (en) 2021-10-26
KR20240119184A (ko) 2024-08-06
US20200261385A1 (en) 2020-08-20
IL261777B2 (en) 2023-02-01
SA518400020B1 (ar) 2022-12-21
HUE059630T2 (hu) 2022-11-28
JP2022106927A (ja) 2022-07-20
DK3429559T3 (da) 2022-07-11
US20210186908A1 (en) 2021-06-24
IL296490A (en) 2022-11-01
PL3429559T3 (pl) 2022-11-07
KR20250150154A (ko) 2025-10-17
US20260076927A1 (en) 2026-03-19
IL261777B (en) 2022-10-01
WO2017160345A1 (en) 2017-09-21

Similar Documents

Publication Publication Date Title
DK3580561T3 (da) Hla-baserede metoder, sammensætninger og anvendelse heraf
PL3694286T3 (pl) Ramki wyzwalające przystosowane do reguł opartych na pakietach w sieci 802.11
PL3628691T3 (pl) Amfifilowe pochodne polisacharydów i zawierające je kompozycje
SI3347472T1 (sl) Sestavki, ki obsegajo polipeptide klada CYP76AD1, in uporabe le-teh
PL4074331T3 (pl) Kompozycje i sposoby internalizacji enzymów
SI3429559T1 (sl) Okusni sestavki, ki vključujejo natrijev fenilbutirat, in njihove uporabe
IL247836A0 (en) 1, 3-benzodioxole derivatives, preparations containing them and their uses
HUE052095T2 (hu) Keratin kezelési készítmények és eljárások
PL3269257T3 (pl) Kompozycja słodzika i żywność ją zawierająca
DK3782617T3 (da) Farmaceutiske gelsammensætninger omfattende levodopa, carbidopa og entacapon
SI3319948T1 (sl) Sestavki kalijevega acesulfama in postopek za izdelavo le-teh
IL284242A (en) Gingerpine lysine suppressants, preparations containing them and their uses
PL3135110T3 (pl) Pochodne 1,7-diarylo-1,6-heptadieno-3,5-dionu, sposób ich wytwarzania i ich zastosowanie
FR3029915B1 (fr) Tripeptides, compositions les comprenant et utilisations notamment cosmetiques
PL3370522T3 (pl) Środek przeciwdrobnoustrojowy zawierający ksantohumol i jego stosowanie w produktach spożywczych
DK3223796T3 (da) Farmaceutiske sammensætninger, fremstilling og anvendelser deraf
DK3608334T3 (da) Tatk-cdkl5-fusionsproteiner, sammensætninger, formuleringer og anvendelse deraf
DK3236934T3 (da) Farmaceutisk sammensætning, fremstilling og anvendelser deraf
SI3337506T1 (sl) Kombinacije in njihove uporabe
HUE057871T2 (hu) Gyógyászati hatóanyagokat tartalmazó hialuronán konjugátumok, eljárások és kompozíciók
DK3229843T3 (da) Farmaceutisk sammensætning, præparat og anvendelser deraf
DK3383397T3 (da) Farmaceutiske sammensætninger indeholdende doravirin, tenofovirdisoproxilfumarat og lamivudin
DK3266310T3 (da) Nukleotidsammensætning og anvendelse i fødevare deraf
IL262119A (en) Storage stable food compositions
SI3097921T1 (sl) Sestavki, ki obsegajo geraniol in suh ingver za uporabo pri zdravljenju sindroma razdražljivega črevesja